Tanja holds a PhD in Neurosciences from the University of Montreal. She then moved to Paris to persue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. Her work was essential in selecting Pharmaleads’ drug candidates, Dual development in the treatment of severe pain.
In 2014, Tanja was appointed Head of Clinical Operations overseeing all operational aspects of the DENKIs clinical trials and was names Director of Clinical Development in 2017.